• Event Type: Q1 FY27 Earnings Conference Call hosted by IIFL Capital

• Date and Time: August 12, 2026 (specific time not mentioned in transcript)

• Purpose: Discussion of Un-audited Standalone and Consolidated Financial Results for the quarter ended June 30, 2026

• Management Participants:

  • Mr. Vikram Vuppala – Chairman and Managing Director
  • Mr. Kamal Shah – Co-Founder
  • Mr. Rohit Singh – Group Chief Executive Officer
  • Mr. Prashant Goenka – Group Chief Financial Officer
  • Moderator: Mr. Naman – IIFL Capital

• Financial Period Discussed: Q1 FY27 (quarter ended June 30, 2026)

• Key Financial Highlights:

  • Revenue: INR282 crores, up 23.7% YoY (from INR228 crores in Q1 FY26)
  • Adjusted EBITDA: INR65.1 crores, up 30.7% YoY
  • Adjusted EBITDA margin: 23.1% (120 bps improvement YoY)
  • Adjusted PAT: INR37 crores, up 41.7% YoY
  • Adjusted PAT margin: 13.1% (from 11.4% in Q1 FY26)
  • Active guests (patients): 38,262, up 13% YoY
  • Treatments: 10.3 lakh, up 13.3% YoY
  • Revenue per treatment: INR2,733, up 9.2% YoY
  • Annualized adjusted ROCE: 21%
  • Capital expenditure: INR44 crores

• Operational Highlights:

  • Network expanded to 550 clinics across 357 cities in 5 countries
  • Added 26 clinics during quarter (19 in India, 7 in Philippines)
  • International operations contribute 45% of revenue
  • Philippines reached milestone of 50 clinics across 39 cities
  • Incorporated subsidiary in Kazakhstan
  • First clinic in Saudi Arabia became operational in July 2026
  • Utilization of IPO proceeds: 68% (INR207 crores) utilized

• Strategic Updates:

  • Three growth levers: increasing guest volumes, expanding footprint in existing countries, entering new countries
  • Medium-term growth guidance maintained at 15-20% over next 3-5 years
  • Launched NephroPlus International Dialysis Academy (NIDA)
  • Implementing AI across organization with process improvements
  • Focus on clinical quality with NephroPlus index and reform.ai application

• Compliance Statement: The conference call contained forward-looking statements based on beliefs, opinions, and expectations of the company as of the date of the call, with appropriate risk disclosures.

Additional Notes Section

• Attachments: The transcript was attached to the regulatory filing and uploaded on the company website at www.nephroplus.com

• Financial Data: Extensive financial and operational data was disclosed in the transcript including revenue, EBITDA, PAT, guest counts, treatment volumes, and expansion metrics

• Regulatory Reference: Filed under Regulation 30, 46(2) and other applicable provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015